Second-generation TKIs: Afatinib is a dual EGFR/HER2 inhibitor that is now FDA-approved for the first-line treatment of lung cancers with EGFR L858R mutations or exon 19 deletions. This evidence concerns the gene ERBB2 and lung carcinoma.